Browsing by Keyword : Sulfonylurea Compounds
Showing results 3 to 11 of 11
Pub Year | | Title | AJOU Author(s) |
2017 | | Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study | 김대중, 김혜진, 박래웅, 윤덕용, 이관우, 한승진 |
2018 | | Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study | 김대중, 김혜진, 이관우, 한승진 |
2007 | | Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. | 김대중, 이관우 |
2018 | | Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program | 김대중, 김혜진, 이관우, 전자영, 한승진 |
2011 | | Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment. | 김혜진 |
2017 | | Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies | 김대중, 이광재 |
2018 | | Long-term effects on glycaemic control and beta-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial | 이관우 |
2023 | | Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study | 김대중 |
2019 | | Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study | 김대중, 하경화 |
1